Stock BRNS BARINTHUS BIOTHERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
2.26 USD -1.74% Intraday chart for Barinthus Biotherapeutics plc -6.99% -38.75%
May. 13 Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective June 3, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
GL
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
AQ
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
GL
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
GL
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
AQ
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
GL
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
GL
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
GL
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
AQ
New partnership aims to advance vaccine against MERS coronavirus
GL
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
GL
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
GL
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
GL
Are we globally prepared for the next pandemic?
AQ
Thinking about buying stock in Pliant Therapeutics, Esperion Therapeutics, Murphy Canyon Acquisition Corp, Limbach Holdings, or Vaccitech?
PR
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
GL
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
AQ
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
GL
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
GL
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRNS Stock
  4. News Barinthus Biotherapeutics plc
  5. Press Releases